Global Hepatitis Drugs Market Is Expected to Grow at a Cagr of 17.1% by 2019: Radiant Insights

Global Hepatitis Drugs Market Share, Size, Trends, Analysis Report 2019: Radiant Insights

About hepatitis
Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

Technavio's analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.

Click For Report Details @

Covered in this report
The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.

Technavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions
• Americas

Key vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Vertex Pharmaceuticals

Other prominent vendors
• Abbvie
• Achillion Pharmaceuticals
• Bristol-Myers Squibb
• Dynavax Technologies
• Mitsubishi Tanabe Pharma

Key Market driver
• Emergence of IFN-free therapies
• For a full, detailed list, view our report

Key Market challenge
• Side-effects of current therapy
• For a full, detailed list, view our report...